A systematic review examines the cellular mechanisms, pharmacokinetic limitations, and available clinical evidence for the ...
Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin Protocol ...
Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ...
Clinical Trials Arena on MSN
Mondego Bio begins Phase Ia trial of oral MB‑388
The trial is assessing single and multiple ascending doses of MB‑388 in healthy volunteers.
InnoCare’s orelabrutinib posts 32.8% durable platelet response in Phase III ITP, topping Sanofi’s rilzabrutinib. NMPA NDA ...
First patient dosed in Phase 2 Vista PD study evaluating VIM0423,a potential first-in-class daily oral therapeutic, for the treatment of refractory tremor in adults with Parkinson’s disease ...
CytomX Therapeutics earns a Buy rating on strong Varseta-M colorectal cancer data, cash runway, and upside potential. Learn ...
Rivia Expands Clinical Trial Intelligence Platform with New AI-Powered Data Findings Module New module enables continuous, automated review of clinical trial data, helping drug developers identify ...
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...
About ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) ...
Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.
Nigeria records 791 additional terrorism convictions in October, bringing the total to 2,512 across 11 trial phases over nine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results